The intricate network of adipokines and stroke

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Kantorová, Ema ^a   Jesenská, ̗ubica ^a   Čierny, Daniel ^a   Zeleňák, Kamil ^a   Sivák, Štefan ^a   Stančík, Matej ^a   Galajda, Peter ^a   Nosá̘, Vladimír ^a   Kurča, Egon ^a  

^a University Teaching Hospital in Martin   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APELIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN;

ADIPOSE TISSUE; BODY MASS; BRAIN ISCHEMIA; DISEASE ASSOCIATION; HUMAN; HYPOADIPONECTINEMIA; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; WAIST CIRCUMFERENCE;

EID: 84953338139     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/967698     Document Type: Review

References (77)

1. T. B. Levine and A. B. Levine, Adipose tissue and overweight, inMetabolic Syndrome and Cardiovascular Disease, S. Pioli, Ed., pp. 264-278, Elsevier, New York, NY, USA, 2nd edition, 2006.
2. A. F. Tarantal and L. Berglund, Obesity and lifespan health-importance of the fetal environment, Nutrients, vol. 6, no. 4, pp. 1725-1736, 2014.
3. P. Trayhurn and J. H. Beattie, Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ, Proceedings of the Nutrition Society, vol. 60, no. 3, pp. 329-339, 2001.
4. G. Fruhbeck, Vasoactive factors and inflammatory mediators produced in adipose tissue, in Nutrition and Health: Adipose Tissue and Adipokines in Health and Disease, G. Fantuzi and T. Mazzoneeds, Eds., pp. 63-77, Humana Press, Totowa, NJ, USA, 2007.
5. G. Matarese, Leptin in autoimmune diseases, in Nutrition and Health: Adipose Tissue and Adipokines in Health and Disease, G. Fantuzzi and T. Mazzone, Eds., pp. 91-100, Humana Press, Totowa, NJ, USA, 2007.
6. B. N. Rocha, P. L. Scalzo, I. G. Barbosa et al., Circulating levels of adipokines in Parkinsons disease, Journal of the Neurological Sciences, vol. 339, no. 1-2, pp. 64-68, 2014.
7. D. R. Gustafson, Adiposity hormones and dementia, Journal of the Neurological Sciences, vol. 299, no. 1-2, pp. 30-34, 2014.
8. B. Boden-Albala, R. L. Sacco, H.-S. Lee et al., Metabolic syndrome and ischemic stroke risk. Northern Manhattan Study, Stroke, vol. 39, no. 1, pp. 30-35, 2008.
9. M. Bosnar-Puretic, V. Basic-Kes, M. J. Jurasic, I. Zavoreo, and V. Demarin, The association of obesity and cerebrovascular disease in young adults-a pilot study, Acta Clinica Croatica, vol. 48, no. 3, pp. 295-298, 2009.
10. H. J. Milionis, E. Rizos, J. Goudevenos, K. Seferiadis, D. P. Mikhailidis, and M. S. Elisaf, Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects, Stroke, vol. 36, no. 7, pp. 1372-1376, 2005.
11. S.-H. Suk, R. L. Sacco, B. Boden-Albala et al., Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study, Stroke, vol. 34, no. 7, pp. 1586-1592, 2003.
12. Y. Winter, S. Rohrmann, J. Linseisen et al., Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks, Stroke, vol. 39, no. 12, pp. 3145-3151, 2008.
13. T. Kurth, J. M. Gaziano, K. Berger et al., Body mass index and the risk of stroke inmen, Archives of Internal Medicine, vol. 162, no. 22, pp. 2557-2562, 2002.
14. S. G. Wannamethee, A. G. Shaper, P. H. Whincup, L. Lennon, and N. Sattar, Adiposity, adipokines, and risk of incident stroke in older men, Stroke, vol. 44, no. 1, pp. 3-8, 2013.
15. J. R. Kizer, M. L. Biggs, J. H. Ix et al., Measures of adiposity and future risk of ischemic stroke and coronary heart disease in older men and women, American Journal of Epidemiology, vol. 173, no. 1, pp. 10-25, 2011.
16. K. K. Andersen and T. S. Olsen, The obesity paradox in stroke: lower mortality and lower risk of readmission for recurrent stroke in obese stroke patients, International Journal of Stroke, vol. 10, no. 1, pp. 99-104, 2015.
17. B. Zebekakis, T. Nawrota, L. Thijsa et al., Obesity is associated with increased arterial stiffness fromadolescence until old age, Journal of Hypertension, vol. 23, no. 10, pp. 1839-1846, 2005.
18. G. Fruhbeck, J. Gomez-Ambrosi, F. J. Muruzabal, and M. A. Burrell, The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation, American Journal of Physiology-Endocrinology and Metabolism, vol. 280, no. 6, pp. 827-847, 2001.
19. M. B. Jackson and R. S. Ahima, Leptin, in Nutrition and Health: Adipose Tissue and Adipokines in Health and Disease, G. Fantuzzi and T. Mazzone, Eds., pp. 35-46, Humana Press Inc, Totowa, NJ, USA, 2007.
20. A. P. Signore, F. Zhang, Z. Weng, Y. Gao, and J. Chen, Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials, Journal of Neurochemistry, vol. 106, no. 5, pp. 1977-1990, 2008.
21. S. S. Martin, A. Quasim, and M. P. Reilly, Leptin resistance, Journal of the American College of Cardiology, vol. 52, pp. 1201-1210, 2008.
22. J. Kaprio, J. Eriksson, M. Lehtovirta, M. Koskenvuo, and J. Tuomilehto, Heritability of leptin levels and the shared genetic effects on body mass index and leptin in adult Finnish twins, International Journal of Obesity, vol. 25, no. 1, pp. 132-137, 2001.
23. J. E. Hall, D. W. Jones, J. J. Kuo, A. da Silva, L. S. Tallam, and J. Liu, Impact of the obesity epidemic on hypertension and renal disease, Current Hypertension Reports, vol. 5, no. 5, pp. 386-392, 2003.
24. S. Soderberg, B. Stegmayr, H. Stenlund et al., Leptin, but not adiponectin, predicts stroke in males, Journal of Internal Medicine, vol. 256, no. 2, pp. 128-136, 2004.
25. C. de Haro Moraes, V. N. Figueiredo, A. P. C. de Faria et al., High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension, Journal of Human Hypertension, vol. 27, no. 4, pp. 225-230, 2013.
26. S. Konstantinides, K. Schafer, S. Koschnick, and D. J. Loskutoff, Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity, Journal of Clinical Investigation, vol. 108, no. 10, pp. 1533-1540, 2001.
27. M. T. Guagnano, M. Romano, A. Falco et al., Leptin increase is associated with markers of the hemostatic system in obese healthy women, Journal ofThrombosis and Haemostasis, vol. 1, no. 11, pp. 2330-2334, 2003.
28. T. Gezmu, D. Schneider, K. Demissie, Y. Lin, C. Giordano, and M. S. Sgizzi, Lipid profiles and ischemic stroke risk: variations by sex within racial/ethnic groups, International Journal of Womens Health, vol. 6, no. 1, pp. 585-594, 2014.
29. J. Labreuche, P.-J. Touboul, and P. Amarenco, Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies, Atherosclerosis, vol. 203, no. 2, pp. 331-345, 2009.
30. E. Kantorova, M. Chomova, E. Kurca et al., Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke, Neuroendocrinology Letters, vol. 32, no. 5, pp. 716-721, 2011.
31. M. J. Mcneely, S. D. Chessler, E. J. Boyko et al., Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans, Diabetes Care, vol. 22, no. 1, pp. 65-70, 1999.
32. J. Liu, K. R. Butler, S. G. Buxbaum, J. H. Sung, B. W. Campbell, and H. A. Taylor, Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study, Clinical Endocrinology, vol. 72, no. 1, pp. 32-37, 2010.
33. A. I. Calleja, E. Cortijo, P. Garcia-Bermejo et al., Blood biomarkers of insulin resistance in acute stroke patients treated with intravenous thrombolysis: temporal profile and prognostic value, Journal of Diabetes Research and ClinicalMetabolism, vol. 2, no. 1, article 2, 2013.
34. C. Savopoulos, K. Michalakis, M. Apostolopoulou, A. Miras, and A. Hatzitolios, Adipokines and stroke: a review of the literature, Maturitas, vol. 70, no. 4, pp. 322-327, 2011.
35. J. Sierra-Johnson, A. Romero-Corral, F. Lopez-Jimenez et al., Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population, The American Journal of Cardiology, vol. 100, no. 2, pp. 234-239, 2007.
36. D. E. Flanagan, J. C. Vaile, G. W. Petley et al., Genderdifferences in the relationship between leptin, insulin resistance and the autonomic nervous system, Regulatory Peptides, vol. 140, no. 1-2, pp. 37-42, 2007.
37. A. Bidulescu, J. Liu, Z. Chen et al., Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in African Americans: the Jackson Heart Study, Front in Endocrin, vol. 1, no. 16, pp. 1-8, 2013.
38. S. Soderberg, B. Stegmayr, C. Ahlbeck-Glader, L. Slunga-Birgander, B. Ahren, and T. Olsson, High leptin levels are associatedwith stroke, CerebrovascularDiseases, vol. 15, no. 1-2, pp. 63-69, 2003.
39. B. G. Windham, M. E. Griswold, S. M. Farasat et al., Influence of leptin, adiponectin, and resistin on the association between abdominal adiposity and arterial stiffness, American Journal of Hypertension, vol. 23, no. 5, pp. 501-507, 2010.
40. M. Ciccone, R. Vettor, N. Pannacciulli et al., Plasma leptin is independently associated with the intima-media thickness of the common carotid artery, International Journal of Obesity, vol. 25, no. 6, pp. 805-810, 2001.
41. G. D. Norata, S. Raselli, L. Grigore et al., Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery, Stroke, vol. 38, no. 10, pp. 2844-2846, 2007.
42. H. Gardener, C. Sjoberg, M. Crisby et al., Adiponectin and carotid intima-media thickness in the Northern Manhattan Study, Stroke, vol. 43, no. 4, pp. 1123-1125, 2012.
43. F. Zhang, S. P. Wang, A. P. Signore, and J. Chen, Neuroprotective effects of leptin against ischemic injury induced by oxygenglucose deprivation and transient cerebral ischemia, Stroke, vol. 38, no. 8, pp. 2329-2336, 2007.
44. I. Sadaf Farooqi, G. Matarese, G. M. Lord et al., Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency, Journal of Clinical Investigation, vol. 110, no. 8, pp. 1093-1103, 2002.
45. G. Anfossi, I. Russo, G. Doronzo, A. Pomero, and M. Trovati, Adipocytokines in atherothrombosis: Focus on platelets and vascular smooth muscle cells, Mediators of Inflammation, vol. 2010, Article ID174341, 26 pages, 2010.
46. T. Damci, S. Tatliagac, Z. Osar, and K. Ilkova, Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia, European Journal of Internal Medicine, vol. 14, no. 6, pp. 357-360, 2003.
47. A. G. Vaiopoulos, K. Marinou, C. Christodoulides, and M. Koutsilieris, The role of adiponectin in human vascular physiology, International Journal of Cardiology, vol. 155, no. 2, pp. 188-193, 2012.
48. M. Nishimura, Y. Izumiya, A. Higuchi et al., Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase-dependent mechanisms, Circulation, vol. 117, no. 2, pp. 216-223, 2008.
49. A. Xu, Y. Wang, and K. S. L. Lam, Adiponectine, in Nutrition and Health: Adipose Tissue and Adipokines in Health and Disease, G. Fantuzzi and T. Mazzone, Eds., pp. 47-59, Humana Press, Totowa, NJ, USA, 2007.
50. S. P. Efstathiou, D. I. Tsioulos, A. G. Tsiakou, Y. E. Gratsias, A. V. Pefanis, and T. D. Mountokalakis, Plasma adiponectin levels and five-year survival after first-ever ischemic stroke, Stroke, vol. 36, no. 9, pp. 1915-1919, 2005.
51. J. Spranger, S. Verma, I. Gohring et al., Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells, Diabetes, vol. 55, no. 1, pp. 141-147, 2006.
52. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, Adipokines in inflammation andmetabolic disease,Nature Reviews Immunology, vol. 11, no. 2, pp. 85-97, 2011.
53. M. Shimabukuro, N. Higa, T. Asahi et al., Hypoadiponectinemia is closely linked to endothelial dysfunction inman, Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 7, pp. 3236-3240, 2003.
54. O. Y. Bang, J. L. Saver, B. Ovbiagele, Y. J. Choi, S. R. Yoon, and K. H. Lee, Adiponectin levels in patients with intracranial atherosclerosis, Neurology, vol. 68, no. 22, pp. 1931-1937, 2007.
55. J. Lo, S. E. Dolan, J. R. Kanter et al., Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women, The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 5, pp. 1677-1682, 2006.
56. B. J. Kim, S.-H. Lee, W.-S. Ryu, C. K. Kim, and B.-W. Yoon, Adipocytokines and ischemic stroke: differential associations between stroke subtypes, Journal of the Neurological Sciences, vol. 312, no. 1-2, pp. 117-122, 2012.
57. M. P. Chen, J. C. Tsai, F. M. Chung et al., Hypoadiponectinemia is associated with ischemic cerebrovascular disease, Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, pp. 821-828, 2005.
58. A. D. Ogorodnikova, S. Wassertheil-Smoller, P. Mancuso et al., High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a womens health initiative study, Stroke, vol. 41, no. 7, pp. 1376-1381, 2010.
59. S. N. Rajpathak, R. C. Kaplan, S. Wassertheil-Smoller et al., Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the womens health initiative, Stroke, vol. 42, no. 7, pp. 1813-1820, 2011.
60. D. J. Stott, P. Welsh, A. Rumley et al., Adipocytokines and risk of stroke in older people: a nested case-control study, International Journal of Epidemiology, vol. 38, no. 1, pp. 253-261, 2009.
61. M. Cnop, P. J. Havel, K. M. Utzschneider et al., Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex, Diabetologia, vol. 46, no. 4, pp. 459-469, 2003.
62. M. Adamczak, E. Rzepka, J. Chudek et al., Ageing and plasma adiponectin concentration in apparently healthy males and females, Clinical Endocrinology, vol. 62, no. 1, pp. 114-118, 2005.
63. R. Carnevale, D. Pastori, M. Peruzzi et al., Total adiponectin is inversely associated with platelet activation and CHA2DS2-VASc score in anticoagulated patients with atrial fibrillation, Mediators of Inflammation, vol. 2014, Article ID908901, 6pages, 2014.
64. D. Estadella, C. M. da PenhaOller doNascimento, L. M. Oyama, E. B. Ribeiro, A. R. Damaso, and A. de Piano, Lipotoxicity: effects of dietary saturated and transfatty acids, Mediators of Inflammation, vol. 2013, Article ID 137579, 13 pages, 2013.
65. C. R. Balistreri, C. Caruso, and G. Candore, The role of adipose tissue and adipokines in obesity-related inflammatory diseases, Mediators of Inflammation, vol. 2010, Article ID 802078, 19 pages, 2010.
66. G. K. Shetty, P. A. Economides, E. S. Horton, C. S. Mantzoros, and A. Veves, Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes, Diabetes Care, vol. 27, no. 10, pp. 2450-2457, 2004.
67. K. Kos, A. L. Harte, N. F. da Silva et al., Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus, The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 3, pp. 1129-1136, 2007.
68. M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. Lazar, and D. J. Rader, Resistin is an inflammatory marker of atherosclerosis in humans, Circulation, vol. 111, no. 7, pp. 932-939, 2005.
69. J. Kochanowski, M. Grudniak, A. Baranowska-Bik et al., Resistin levels in women with ischemic stroke, Neuroendocrinology Letters, vol. 33, no. 6, pp. 603-607, 2012.
70. S. Verma, S.-H. Li, C.-H. Wang et al., Resistin promotes endothelial cell activation: further evidence of adipokineendothelial interaction, Circulation, vol. 108, no. 6, pp. 736-740, 2003.
71. F. Lago, C. Dieguez, J. Gomez-Reino, and O. Gualillo, Adipokines as emerging mediators of immune response and inflammation, Nature Clinical Practice Rheumatology, vol. 3, no. 12, pp. 716-724, 2007.
72. K. S. Chong, R. S. Gardner, J. J. Morton, E. A. Ashley, and T. A. McDonagh, Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure, European Journal of Heart Failure, vol. 8, no. 4, pp. 355-360, 2006.
73. P. T. Ellinor, A. F. Low, and C. A. MacRae, Reduced apelin levels in lone atrial fibrillation, European Heart Journal, vol. 27, no. 2, pp. 222-226, 2006.
74. J.-C. Zhong, X.-Y. Yu, Y. Huang, L.-M. Yung, C.-W. Lau, and S.-G. Lin, Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice, Cardiovascular Research, vol. 74, no. 3, pp. 388-395, 2007.
75. N. P. E. Kadoglou, G. Fotiadis, V. Lambadiari, E. Maratou, G. Dimitriadis, and C. D. Liapis, Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis, Peptides, vol. 57, pp. 12-16, 2014.
76. C.-G. Yin, L. Jiang, B. Tang, H. Zhang, Q. Qian, and G.-Z. Niu, Prognostic significance of plasma visfatin levels in patients with ischemic stroke, Peptides, vol. 42, pp. 101-104, 2013.
77. T. B. Dahl, A. Yndestad, M. Skjelland et al., Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization, Circulation, vol. 115, no. 8, pp. 972-980, 2007